Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3118-3126

  Vallon Eberhard, Alexandra ^a   Makovitzki, Arik ^a   Beauvais, Anne ^b   Latgé, Jean Paul ^b   Jung, Steffen ^a   Shai, Yechiel ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; POLYPEPTIDE ANTIBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONFOCAL MICROSCOPY; CONIDIUM; CONTROLLED STUDY; DRUG SCREENING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; HUMANS; IMMUNOCOMPROMISED HOST; LIPOPROTEINS; LUNG; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PEPTIDES; TREATMENT OUTCOME;

EID: 50949089497     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00526-08     Document Type: Article

References (34)

1. Baddley, J. W., T. P. Stroud, D. Salzman, and P. G. Pappas. 2001. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis. 32:1319-1324.
2. Bowden, R., P. Chandrasekar, M. H. White, X. Li, L. Pietrelli, M. Gurwith, J. A. van Bunk, M. Laverdiere, S. Safrin, and J. R. Wingard. 2002. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35:359-366.
3. Bozza, S., R. Gaziano, A. Spreca, A. Bacci, C. Montagnoli, P. di Francesco, and L. Romani. 2002. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J. Immunol. 168:1362-1371.
4. Caillot, D., H. Bassaris, A. McGeer, C. Arthur, H. G. Prentice, W. Seifert, and K. De Beule. 2001. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin. Infect. Dis. 33:e83-e90.
5. Clark, J. M., R. R. Whitney, S. J. Olsen, R. J. George, M. R. Swerdel, L. Kunselman, and D. P. Bonner. 1991. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35:615-621.
6. Clemens, K. V., and D. A. Stevens. 2004. Comparative efficacies of four amphotericin B formulations - fungizone, amphotec (Amphocil), AmBisome, and Abelcet - against systemic murine aspergillosis. Antimicrob. Agents Chemother. 48:1047-1050.
7. Denning, D. W. 1998. Invasive aspergillosis. Clin. Infect. Dis. 26:781-803.
8. Dubourdeau, M., R. Athman, V. Balloy, M. Huerre, M. Chignard, D. J. Philpott, J. P. Latge, and O. Ibrahim-Granet. 2006. Aspergillus fumigatus induces innate immune responses in alveolar macrophages through the MAPK pathway independently of TLR2 and TLR4. J. Immunol. 177:3994-4001.
9. Erjavec, Z., G. M. Woolthuis, H. G. de Vries-Hospers, W. J. Sluiter, S. M. Daenen, B. de Pauw, and M. R. Halie. 1997. Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur. J. Clin. Microbiol. Infect. Dis. 16:364-368.
10. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Riband. O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
11. Ho, W., and A. Furst. 1973. Intratracheal instillation method for mouse lungs. Oncology 27:385-393.
12. 3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20:4106-4114.
13. Landsman, L., C. Varol, and S. Jung. 2007. Distinct differentiation potential of blood monocyte subsets in the lung. J. Immunol. 178:2000-2007.
14. Latge, J. P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:310-350.
15. Leenders, A. C., S. Daenen, R. L. Jansen, W. C. Hop, B. Lowenberg, P. W. Wijermans, J. Cornelissen, R. Herbrecht, H. van der Lelie, H. C. Hoogsteden, H. A. Verbrugh, and S. de Marie. 1998. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol 103:205-212.
16. Makovitzki, A., D. Avrahami, and Y. Shai. 2006. Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl. Acad. Sci. USA 103:15997-16002.
17. Makovitzki, A., and Y. Shai. 2005. pH-dependent antifungal lipopeptides and their plausible mode of action. Biochemistry 44:9775-9784.
18. Marr, K. A., R. A. Carter, F. Crippa, A. Wald, and L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917.
19. Mylonakis, E., T. F. Barlam, T. Flanigan, and J. D. Rich. 1998. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 114: 251-262.
20. Olson, J. A., J. P. Adler-Moore, J. Schwartz, G. M. Jensen, and R. T. Proffitt. 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother. 50:2122-2131.
21. Pai, M. P., and A. L. Jones. 2004. Altered susceptibility of Candida glabrata bloodstream isolates to triazoles at clinically relevant pH values: comparison of the NCCLS M27-A2, Sensititre YeastOne, and Etest methods. Antimicrob. Agents Chemother. 48:4441-4443.
22. Perfect, J. R., M. E. Klotman, C. C. Gilbert, D. D. Crawford, G. L. Rosner, K. A. Wright, and W. P. Peters. 1992. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J. Infect. Dis. 165:891-897.
23. Philippe, B., O. Ibrahim-Granet, M. C. Prevost, M. A. Gougerot-Pocidalo, M. Sanchez Perez, A. Van der Meeren, and J. P. Latge. 2003. Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect. Immun. 71:3034-3042.
24. Rieg, G., B. Spellberg, J. Schwartz, Y. Fu, J. E. Edwards, Jr., D. C. Sheppard, and A. S. Ibrahim. 2006. Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50:2895-2896.
25. Schaffner, A., H. Douglas, and A. Braude. 1982. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J. Clin. Investig. 69:617-631.
26. Schwartz, S., G. Behre, V. Heinemann, H. Wandt, E. Schilling, M. Arning, A. Trittin, W. V. Kern, O. Boenisch, D. Bosse, K. Lenz, W. D. Ludwig, W. Hiddemann, W. Siegert, and J. Beyer. 1999. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 93:3654-3661.
27. Stevens, D. A., V. L. Kan, M. A. Judson, V. A. Morrison, S. Dummer, D. W. Denning, J. E. Bennett, T. J. Walsh, T. F. Patterson, and G. A. Pankey for the Infectious Diseases Society of America. 2000. Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 30:696-709.
28. Tollemar, J., O. Ringden, S. Andersson, B. Sundberg, P. Ljungman, and G. Tyden. 1993. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 12:577-582.
29. Vallon-Eberhard, A., L. Landsman, N. Yogev, B. Verrier, and S. Jung. 2006. Transepithelial pathogen uptake into the small intestinal lamina propria. J. Immunol. 176:2465-2469.
30. Wald, A., W. Leisenring, J. A. van Burik, and R. A. Bowden. 1997. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. 175:1459-1466.
31. Walsh, T. J., J. L. Goodman, P. Pappas, I. Bekersky, D. N. Buell, M. Roden, J. Barrett, and E. J. Anaissie. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45:3487-3496.
32. Walsh, T. J., J. W. Hiemenz, and E. Anaissie. 1996. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect. Dis. Clin. North Am. 10:365-400.
33. Walsh, T. J., J. W. Hiemenz, N. L. Seibel, J. R. Perfect, G. Horwith, L. Lee, J. L. Silber, M. J. DiNubile, A. Reboli, E. Bow, J. Lister, and E. J. Anaissie. 1998. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26:1383-1396.
34. Wingard, J. R., P. Kubilis, L. Lee, G. Yee, M. White, L. Walshe, R. Bowden, E. Anaissie, J. Hiemenz, and J. Lister. 1999. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29:1402-1407.